[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "US vaccine intervals increased", "description": "But infections go down in US and UK\nFree download of my 2 textbooks\n\nhttp://159.69.48.3/\n\nPhysiology book in hard copy\nhttps://www.ebay.co.uk/itm/154770452796?mkevt=1&mkcid=16&mkrid=710-127635-2958-0\n\nUnited States\n\nCases, + 84,406, down 66% last 2 weeks\n\nHospitalized, 54,247, down 44% last 2 weeks\n\nDeaths, + 3,025, down 26% last 2 weeks = 940,405\n\nNew York City\n\nCases, 1,055, down 3% on the day\n\nDown 56% last 2 weeks\n\nDeaths, down 62% last 2 weeks\n\nConsiderations for intervals for mRNA COVID-19 vaccine primary series\n\nhttps://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html\n\nhttps://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series\n\nAn 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12 to 39 years.\n\nWhile absolute risk remains small, the relative risk for myocarditis is higher for males ages 12-39 years, \n\nand this risk might be reduced by extending the interval between the first and second dose\n\nPeak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks.\n\nPoland\n\nhttps://www.nytimes.com/live/2022/02/24/world/covid-19-tests-cases-vaccine?      campaign_id=185&emc=edit_yct_20220224&instance_id=54145&nl=coronavirus-tracker&regi_id=110300449&segment_id=83814&te=1&user_id=0b87b8c1eea981ec0514047bbfa553ca#poland-covid-restrictions\n\nLift most of remaining restrictions on March 1\n\nPrime Minister Mateusz Morawiecki \n\nDeaths and hospitalizations, Omicron variant, lower than anticipated,\n\nEncouraging trends made the risk of shifting to an endemic approach worthwhile\n\nCases, + 20,456 30% down on the week\n\nFully vaccinated 58%\n\nGermany\n\nMarch 20th most restrictions go\n\nUK\n\nHMQ, cancelled events\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\nWeek ending 19 February 2022 \n\n2,096,200 people (1 in 25) in England\n\n98,200 people (1 in 30) in Wales\n\n132,700 people (1 in 14) in Northern Ireland\n\n240,700 people (1 in 20) in Scotland\n\nThe rate of reinfections sharply increased\n\nThe reinfection rate increased from 11.7 to 141.1 per 100,000 people since the Omicron variant became most common.\n\nThe risk of reinfection was ten times higher when the Omicron variant was most common (20 December 2021 to 6 February 2022) \n\ncompared with when the Delta variant was most common (17 May 2021 to 19 December 2021)\n\nPeople who had their second vaccine dose over 90 days ago were more likely to be reinfected than people who had it 14 to 89 days ago.", "link": "https://www.youtube.com/watch?v=m3YKFdP0wt0", "date_published": "2022-02-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Inflammatory Syndrome in Children", "description": "Cases of this severe disease in children are very low in omicron times\n\nOriginal video for solar lights,\nhttps://www.youtube.com/watch?v=dY-IatTFJGM&t=150s\n\nWefwafwa's channel, please subscribe to help support this work, \nhttps://www.youtube.com/channel/UCzsLklGgOttU3Se-WGLp7ow\n\nE mail for Wefwafwa\nwefandrew@gmail.com\n\nPlease e mail Wefwafwa if you would like to be involved in this community health project\n\nMIS-C COVID\n\nOverall cases in children this year, 4.6 million\n\nMultisystem Inflammatory Syndrome\n\n\nWhat is MIS?\n\nMIS is a rare but serious condition associated with COVID-19 in which different body parts become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs.\n\nhttps://amp.cnn.com/cnn/2022/02/22/health/mis-c-omicron-waiting-for-trouble/index.html\n\nhttps://covid.cdc.gov/covid-data-tracker/#mis-national-surveillance\n\nTotal MIS-C cases, 6,851\n\nDeaths, 59\n\nChild cases, 12.5 million since start of pandemic\n\nChildren, 0.00%-0.25% of all COVID-19 deaths\n\nhttps://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/\n\n\nThe median age 9 years\n\nHalf of children with MIS-C were between the ages of 5 and 13 years.\n\n60% of reported patients were male.\n\n59% of the reported patients Hispanic/Latino or black\n\nBlack, 2,050 \n\nHispanic/Latino, 1,746\n\n98% of patients had a positive test result for SARS CoV-2\n\n2% of patients had contact with someone with COVID-19\n\nMIS-C can occur weeks after COVID-19 and even if the child or family did not know the child had COVID-19.\n\nClinical Criteria\n\nFever, \u226538.0 C) for \u226524 hours\n\nShock or hypotension\n\nSevere cardiac illness\n\nmyocarditis, pericarditis, coronary artery dilatation/aneurysm\nnew-onset right or left ventricular dysfunction\n2nd/3rd degree A-V block\nventricular tachycardia\n\nRash AND non-purulent conjunctivitis\n\nNew-onset neurologic signs and symptoms\n\nEncephalopathy, seizures, meningeal signs, or peripheral\u202fneuropathy (including Guillain-Barr\u00e9 syndrome) \n\nAbdominal pain, vomiting, or diarrhea\n\nThrombocytopenia\n\nElevated inflammatory markers\n\nA positive SARS-CoV-2 test for current or recent infection by RT-PCR, serology, or antigen detection\n\nDr. Roberta DeBiasi, Infectious Disease Division chief at Children's National Hospital, Washington, DC\n\nIt always follows the same pattern\n\nIt's always two to six weeks after we see the spike from whatever variant it is,\n\nand then we're on the lookout for MIS-C. And then, sure enough, it comes.\"\n\nsome of the MIS-C patients have been vaccinated, but the vast majority are not\n\nwe thought we may see an uptick with Omicron, but we haven't. \n\nUniversity of Pittsburgh Medical Center, Dr. Marian Michaels\n\nLuckily, in our area we are not seeing a surge\n\nI'm very grateful\n\nSeattle Children's Dr. Michael Portman, director of research in the Division of Cardiology\n\nMore MIS-C cases since mid-December 2021\n\nhttps://www.ahajournals.org/doi/10.1161/JAHA.121.023251\n\nmost children with MIS-C begin recovering in the first week after hospital discharge and fully recover heart function within three months", "link": "https://www.youtube.com/watch?v=qlBLZaw2DkY", "date_published": "2022-02-23 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Natural immunity, answers", "description": "If you would like John\u2019s text books, (it is free to download the PDFs)\n\nLink to free download of my 2 textbooks\n\nhttp://159.69.48.3/\n\nPhysiology book in hard copy\n\nhttps://www.ebay.co.uk/itm/154770452796?mkevt=1&mkcid=16&mkrid=710-127635-2958-0\n\nDo you also have significant protection even after previous asymptomatic infection?\n\nStefan\u2019s original paper\n\nhttps://pubmed.ncbi.nlm.nih.gov/35149106/\n\nOriginal video\n\nhttps://www.youtube.com/watch?v=s-E7HNWZW-k\n\nQuestion 1: Do you also have a significant protection against reinfections when your first SARS-CoV-2 infection was asymptomatic?\n\nAnswer: Yes\n\nhttps://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciac034/6509535?redirectedFrom=PDF\n\nAccepted article, Clinical Infectious Diseases\n\nReinfection with delta data\n\nPrevious infection reduced hospitalizations by 85%\n\nEffectiveness against symptomatic reinfection\n\nProtection from symptomatic versus asymptomatic infection\n\nSymptomatic previous infection, 92.9% protection\n\nAsymptomatic previous infection, 85.9% protection\n\nboth symptomatic and asymptomatic infection appear to provide strong protection against future severe disease.\n\nThese data are extremely important as so many infections are asymptomatic\n\n \nQuestion 2: Are the data on natural immunity also valid for the Omicron variant?\n\nAnswer: Yes, (Letter to NEJM)\nProtection against the Omicron Variant from Previous SARS-CoV-2 Infection\n\nQatar\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMc2200133\n\nIn addition, we performed\nsensitivity analyses that included adjustment for vaccination status and that excluded vaccinated persons from the analysis.\n\nProtection against reinfections is moderately lower for the Omicron variant\n\nThe effectiveness of previous infection in preventing reinfection was estimated to be \n\n90.2% against the alpha variant \n\n85.7% against the beta variant, \n\n92.0% against the delta variant, and \n\n56.0%magainst the omicron variant\n\nProtection against severe, critical or fatal COVID-19 is similar as for other variants\n\nThe effectiveness with respect to\nsevere, critical, or fatal Covid-19\n\n69.4% against the alpha variant, \n\n88.0% against the beta variant\n\n95% to 100% against the delta variant\n\n87.8% against the omicron variant\n\nThe median interval between previous infection and PCR testing\n\n254 days to 376 days\n\nQuestion 3: Is Omicron really not so mild?\n\nNEJM, Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMp2119682\n\nSouth Africa\n\nAnswer: According to data from individuals who remained unvaccinated and did not have a previous SARS-CoV-2 infection, \n\nthe severity in terms of causing hospitalization was about 75% of the Delta variant.\n\nViruses don\u2019t inevitably evolve toward being less virulent; \n\nevolution simply selects those that excel at multiplying. \n\nIn the case of Covid-19, in which the vast majority of transmission occurs before disease becomes severe, \n\nreduced severity may not be directly selected for at all. \n\nIndeed, previous SARS-CoV-2 variants with enhanced transmissibility (e.g., alpha and delta) \n\nappear to have greater intrinsic severity than their immediate ancestors or the previously dominant variant.", "link": "https://www.youtube.com/watch?v=HMsAJzwKwVY", "date_published": "2022-02-23 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]